You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
AEGIS: A Pixel-array Readout IC for Gamma-ray Imaging
SBC: Augustine Engineering Topic: N/ADESCRIPTION (provided by applicant): CdZnTe arrays are promising detectors for improving nuclear medicine imaging, but existing CdZnTe cameras have limited spatial resolution and small numbers of pixels (space bandwidth product = SpBW). We show that major performance improvements will require high SpBW (>10A5) and small pixels (high resolution). The best approach to obtaining high SpBW detectors i ...
STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health -
Novel lipid-based therapies for cystic fibrosis
SBC: AVRION MOLECULAR, INC. Topic: N/ADESCRIPTION (provided by applicant): Although the genetic cause of cystic fibrosis (CF), a lethal autosomal disorder, has been known for over a decade, an effective therapeutic method is still lacking. Pulmonary disease remains the major cause of morbidity and mortality in CF. The CF lung is marked by dysregulated inflammation and chronic infection, the end result being progressive bronchiectatic ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Mobile Training of Skilled Support Personnel
SBC: BANDEMAR NETWORKS, LLC Topic: N/ADESCRIPTION (provided by applicant) Skilled Service Personnel (SSP) support emergency response organizations during an emergency incident involving weapons of mass destruction and include laborers, operating engineers, carpenters, ironworkers, sanitation workers and utility workers. SSP called to an emergency incident rarely have recent detailed training on the chemical, biological, radiological, ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Mobile Just-In-Time Training of Emergency Response Personnel- Phase II
SBC: BANDEMAR NETWORKS, LLC Topic: N/ADESCRIPTION (provided by applicant): Skilled Service Personnel (SSP) support emergency response organizations during an emergency incident, and include laborers, operating engineers, carpenters, ironworkers, sanitation workers and utility workers. SSP called to an emergency incident rarely have recent detailed training on the chemical, biological, radiological, nuclear and/or explosives (CBRN ...
STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
New Opioids for Alcoholism
SBC: BEHAVIORAL PHARMA, INC. Topic: N/ADESCRIPTION (provided by applicant): Highly potent, orally active, metabolically stable, long-lived opioid agents for the treatment of alcoholism that have decreased side effects such as nausea, addiction liability, immunosuppression and respiratory depression represents a great unmet need. While a mu opioid receptor antagonist is currently approved by the FDA for alcoholism, it possesses several ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Progenitor assay to screen proteins/molecules for treatment of type1 diabetes
SBC: BETASTEM THERAPUETICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Human embryonic stem cells (HuES) have the potential to generate an unlimited source of beta/islet cells for transplantation, however the biologic factors required for this process have been difficult to ascertain partly due to the lack of stage specific in vitro cell assays. Recently, we have developed a murine in vitro pancreatic stem/progenitor colony assay ...
STTR Phase I 2007 Department of Health and Human ServicesNational Institutes of Health -
NOVEL THERAPEUTIC APPROACH TO PSORIASIS
SBC: BETHESDA PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (Applicant's abstract): Psoriasis is a common, inflammatory disease of the skin characterized by hyper-proliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. Thiaz ...
STTR Phase II 2001 Department of Health and Human ServicesNational Institutes of Health -
NOVEL THERAPEUTIC APPROACH TO PSORIASIS
SBC: BETHESDA PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (Applicant's abstract): Psoriasis is a common, inflammatory disease of the skin characterized by hyper-proliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. Thiaz ...
STTR Phase I 2001 Department of Health and Human ServicesNational Institutes of Health -
New Topical Therapies for Psoriasis
SBC: BETHESDA PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): Psoriasis is a common, inflammatory disease of the skin characterized by hyperproliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. In the current studies, we will ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
New Topical Therapies for Psoriasis
SBC: BETHESDA PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): Psoriasis is a common, inflammatory disease of the skin characterized by hyperproliferation of keratinocytes. A variety of antipsoriatic therapies are available, however, due to problems with side effects and variability in clinical response, intense clinical and commercial interest remains in the development of new treatments. In the current studies, we are in ...
STTR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health